Home Newsfeeds Wolfe Research Downgrades W.W. Grainger to Peer Perform

Wolfe Research Downgrades W.W. Grainger to Peer Perform

Wolfe Research analyst Nigel Coe downgrades W.W. Grainger (NYSE:GWW) from Outperform to Peer Perform.

byBenzinga Newsdesk

November 14, 2022

1 minute read

Wolfe Research analyst Nigel Coe downgrades W.W. Grainger (NYSE:GWW) from Outperform to Peer Perform.

Reported Late Thursday March 23, PolyMet Mining Reports Results For Year Ended December 31, 2022; Cash Used In Investing Activities For The Year Ended December 31, 2022, Was $8M Compared With $6.9M YoY

By Happy Mohamed

March 24, 12:56 AM

PolyMet Mining Corp. (TSX:POM) (NYSE:PLM) ("PolyMet" or the "company"), today reports it has filed its financial results for the year ended December 31, 2022 and provides a first

PLM

Aethlon Medical Secures FDA Clearance For Amendment In Initial-Stage COVID-19 Study

By Ragothaman Srinivasan

July 11, 11:41 AM

The U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol of the ongoing clinical trial investigating Aethlon Medical’s (NASDAQ: AEMD) lead therapy Aethlon Hemopurifier for patients with severe COVID-19.

AEMD

Will AT&T’s Latest Strategies Impress the Market? Analyst Weighs In On Potential Impact And New Ericsson Deal

By Anusuya Lahiri

December 12, 2:33 PM

Oppenheimer analyst Timothy Horan had a Perform rating on AT&T Inc (NYSE: T). The analyst hosted Pascal Desroches, CFO, at its 5G conference yesterday.

ERIC

EF Hutton Initiates Coverage On Bone Biologics with Buy Rating, Announces Price Target of $2.25

By Benzinga Newsdesk

October 18, 7:45 AM

EF Hutton analyst Constantine Davides initiates coverage on Bone Biologics (NASDAQ:BBLG) with a Buy rating and announces Price Target of $2.25.

BBLG

Wolfe Research Downgrades W.W. Grainger to Peer Perform

Related Posts

Reported Late Thursday March 23, PolyMet Mining Reports Results For Year Ended December 31, 2022; Cash Used In Investing Activities For The Year Ended December 31, 2022, Was $8M Compared With $6.9M YoY

Aethlon Medical Secures FDA Clearance For Amendment In Initial-Stage COVID-19 Study

Will AT&T’s Latest Strategies Impress the Market? Analyst Weighs In On Potential Impact And New Ericsson Deal

EF Hutton Initiates Coverage On Bone Biologics with Buy Rating, Announces Price Target of $2.25